CFBP inhibitors are a class of compounds that specifically target and inhibit the activity of cytosolic fructose-1,6-bisphosphatase (CFBP), an enzyme that plays a key role in the metabolic pathway of gluconeogenesis. CFBP is responsible for catalyzing the conversion of fructose-1,6-bisphosphate into fructose-6-phosphate, an essential step in the production of glucose from non-carbohydrate sources. This enzyme functions to regulate the balance between glycolysis and gluconeogenesis, ensuring proper energy homeostasis within cells. By inhibiting CFBP, these compounds block the enzyme's ability to facilitate this metabolic conversion, which can lead to changes in glucose production and energy metabolism within the cell.
The mechanism of action for CFBP inhibitors typically involves binding to the enzyme's active site or altering its conformation to prevent substrate interaction. This inhibition interrupts the normal metabolic flow of gluconeogenesis, making these inhibitors useful in research exploring energy regulation, metabolic flux, and the cellular response to varying levels of glucose availability. CFBP inhibitors allow scientists to investigate how disruptions in fructose-1,6-bisphosphate processing affect broader metabolic pathways, particularly those involved in energy production and glucose homeostasis. By modulating CFBP activity, researchers can gain insight into the enzyme's specific contributions to cellular metabolism, energy storage, and the regulation of glucose-producing pathways, providing a clearer understanding of how metabolic enzymes coordinate complex biochemical processes.
Items 11 to 11 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Daclatasvir | 1009119-64-5 | sc-500663 | 100 mg | $330.00 | ||
Blocks clathrin-dependent endocytosis, potentially altering endosomal trafficking and ESCRT machinery function. | ||||||